Screener
BridgeBio Pharma BBIO Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31, 2026 / Weighted-average Estimated Useful Lives | March 31, 2026 / Amount | December 31, 2025 / Weighted-average Estimated Useful Lives | December 31, 2025 / Amount |
|---|---|---|---|---|
| Gross amount | 13.7 years | $39,400 | 13.7 years | $39,400 |
| Less accumulated amortization | (12,041) | (11,323) | ||
| Total | $27,359 | $28,077 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's finite lived intangible assets - gross?
- BridgeBio Pharma (BBIO) reported finite lived intangible assets - gross of $39.4M in Q1 2026.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.
Ask your AI about BridgeBio Pharma's finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude